Xtant Medical Q1 2026 net loss $3.1M; revenue falls to $20.9M, raises 2026 guidance to $101-105M

Xtant Medical Holdings, Inc.

Q1 2026 revenue $20.9M vs $32.9M YoY; decline driven by asset sale to Companion Spine and license revenue ceasing.
Net loss of $3.1M vs net income of $58K in Q1 2025; non-GAAP adjusted EBITDA loss $1.6M vs +$3.0M.
Full-year 2026 revenue guidance raised to $101-105M from $95-99M reflecting HEMOBLAST incremental revenue.
Entered exclusive US distribution for Dilon Technologies' HEMOBLAST Bellows; hired approx. 20-person sales team.
Reduced total indebtedness by $13.3M; cash $12.2M, availability under revolver $11.8M as of March 31, 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2026 results: revenue $20.9 million, net income net loss was $3.1 million. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: $20.9 million
Net income: net loss was $3.1 million
Guidance: raised
Result: reported results

Exact text from the filing

conditions, today reported financial and operating results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights ● Generated total revenue of $20.9 million for the first quarter of 2026, as compared to $32.9 million for the first quarter of 2025. The decline in revenue relates primarily to the sale of assets and businesses to

View on SEC.gov

Browse all earnings releases →

Xtant Medical Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-022600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.